Histone deacetylase inhibitor for NUT midline carcinoma

Ossama M. Maher; Anthony M. Christensen; Sireesha Yedururi; Diana Bell; Nidale Tarek

doi:10.1002/pbc.25350

journal article Jan 03, 2015

Histone deacetylase inhibitor for NUT midline carcinoma

Ossama M. Maher Anthony M. Christensen Sireesha Yedururi

Diana Bell Nidale Tarek

Pediatric Blood & Cancer Vol. 62 No. 4 pp. 715-717 · Wiley

View at Publisher Save 10.1002/pbc.25350

Topics

No keywords indexed for this article. Browse by subject →

References

15

[1]

Kubonishi "Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma" Cancer Res (1991)

[2]

French "Pathogenesis of NUT midline carcinoma" Annu Rev Pathol (2012) 10.1146/annurev-pathol-011811-132438

[3]

French "The importance of diagnosing NUT midline carcinoma" Head Neck Pathol (2013) 10.1007/s12105-013-0428-1

[4]

Stelow "A review of NUT midline carcinoma" Head Neck Pathol (2011) 10.1007/s12105-010-0235-x

[5]

Haack "Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody" Am J Surg Pathol (2009) 10.1097/pas.0b013e318198d666

[6]

Evans "Pathologic characteristics of NUT midline carcinoma arising in the mediastinum" Am J Surg Pathol (2012) 10.1097/pas.0b013e318258f03b

[7]

French "NUT midline carcinoma" Cancer Genet Cytogenet (2010) 10.1016/j.cancergencyto.2010.06.007

[8]

Bauer "Clinicopathologic features and long-term outcomes of NUT midline carcinoma" Clin Cancer Res (2012) 10.1158/1078-0432.ccr-12-1153

[9]

French "Midline carcinoma of children and young adults with NUT rearrangement" J Clin Oncol (2004) 10.1200/jco.2004.02.107

[10]

Schwartz "Differentiation of NUT midline carcinoma by epigenomic reprogramming" Cancer Res (2011) 10.1158/0008-5472.can-10-3513

[11]

Selective inhibition of BET bromodomains

Panagis Filippakopoulos, Jun Qi, Sarah Picaud et al.

Nature 2010 10.1038/nature09504

[12]

Munshi "Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci" Mol Cancer Ther (2006) 10.1158/1535-7163.mct-06-0022

[13]

Ree "Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study" Lancet Oncol (2010) 10.1016/s1470-2045(10)70058-9

[14]

Hummel "A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study" Pediatr Blood Cancer (2013) 10.1002/pbc.24541

[15]

Fouladi "Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report" J Clin Oncol (2010) 10.1200/jco.2009.25.9119

Cited By

68

International guidelines on the diagnosis and treatment of NUT carcinoma

Yu Zhang, Qi Zhang · 2026

The Innovation

Metrics

68

Citations

15

References

Details

Published: Jan 03, 2015
Vol/Issue: 62(4)
Pages: 715-717
License: View

Authors

O

Ossama M. Maher

Department of Pediatrics; University of Texas; MD Anderson Cancer Center; Houston Texas; Department of Pediatrics; National Cancer Institute, Cairo University; Cairo Egypt

A

Anthony M. Christensen

Department of Pharmacy Clinical Programs; University of Texas; MD Anderson Cancer Center; Houston Texas

S

Sireesha Yedururi

Department of Radiology; University of Texas; MD Anderson Cancer Center; Houston Texas

D

Diana Bell

Department of Pathology; University of Texas; MD Anderson Cancer Center; Houston Texas

N

Nidale Tarek

Department of Pediatrics; University of Texas; MD Anderson Cancer Center; Houston Texas

Cite This Article

Ossama M. Maher, Anthony M. Christensen, Sireesha Yedururi, et al. (2015). Histone deacetylase inhibitor for NUT midline carcinoma. Pediatric Blood & Cancer, 62(4), 715-717. https://doi.org/10.1002/pbc.25350

Histone deacetylase inhibitor for NUT midline carcinoma

You May Also Like